Eagle Pharmaceuticals ( (EGRX) ) just unveiled an update.
Eagle Pharmaceuticals has appointed Christopher Krawtschuk as its new Chief Financial Officer, effective November 11, 2024. With a rich background in finance and experience in the pharmaceutical sector, including roles at bluebird bio and Jubilant Pharma, Krawtschuk is expected to bring valuable insight to Eagle’s operations. His appointment coincides with the stepping down of interim CFO Steven Ratoff, who will remain on Eagle’s board. This leadership change aims to strengthen Eagle’s financial strategy and support its growth ambitions in the pharmaceutical market.
Find detailed analytics on EGRX stock on TipRanks’ Stock Analysis page.
